ReviewFrontiers in cardiovascular medicine2026
Artificial intelligence-empowered echocardiography: an updated review of clinical management in hypertrophic cardiomyopathy.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertrophic cardiomyopathy (HCM) is a common and highly heterogeneous inherited cardiomyopathy characterized by complex clinical phenotypes and diverse disease trajectories, posing significant challenges for early diagnosis, precise phenotypic classification, and risk stratification. Owing to its noninvasive nature, repeatability, and wide availability, echocardiography remains the cornerstone imaging modality for the diagnosis and longitudinal management of HCM. However, conventional echocardiographic analysis relies heavily on operator expertise and is limited in its ability to comprehensively extract latent structural, functional, and tissue-level information embedded within imaging data. In recent years, artificial intelligence (AI), particularly deep learning, has undergone rapid development in automated echocardiographic analysis, enabling a paradigm shift from traditional morphology-based assessment toward data-driven intelligent decision-support platforms. This review systematically categorizes AI-based methods in echocardiography according to the complexity of data processing, ranging from single-frame structural and texture analysis to spatiotemporal modeling of cardiac function, multi-view representation learning, and ultimately multimodal integration incorporating diverse clinical data sources. We further summarize the clinical applications of these AI-based methods in HCM, including diagnosis and differential diagnosis, phenotype characterization, and risk prediction. In addition, current challenges are discussed, including limited interpretability, data heterogeneity, and insufficient large-scale clinical validation, and future research directions are proposed. Overall, AI-empowered echocardiography holds substantial promise for advancing precision diagnosis, risk stratification, and personalized management of HCM, facilitating a transition toward more intelligent and individualized cardiovascular care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.